Day: September 29, 2021

SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and benign prostatic hyperplasia (BPH) (the “Product”), Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive”), has entered into a definitive license and supply agreement (the “Agreement”) with an undisclosed leading men’s health company. “Securing this commercial partnership is a significant milestone in our innovative collaboration with Aquestive, and represents another major step toward achieving our mutual goal of making Tadalafil oral films available to men suffering from ED and BPH,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. About Aquestive Therapeutics Aquestive...

HOUSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings via video conference at the Wolfe Research Utilities, Midstream & Clean Energy Conference on Thursday, September 30, 2021. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary...

MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:Date:   Thursday, September 30, 2021  Time:    10:10AM ETWebcast Link:   https://www.benzinga.com/events/small-cap/healthcare/The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.pasithea.com, under the Investors section. About Pasithea Therapeutics Corp. Pasithea Therapeutics Corp. is a biotechnology company focused on the research and...

SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing of its previously announced registered direct offering for the purchase and sale of 77,777,779 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 77,777,779 shares of common stock, at an effective purchase price of $0.09 per share (or common stock equivalent in lieu thereof) and associated warrant. H.C. Wainwright & Co. acted as the exclusive placement agent for the registered direct offering. The warrants have an exercise price equal to $0.09 per share, are exercisable...

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its third quarter 2021 financial results after market close on Wednesday, October 27, 2021. Senior management will host a conference call on Thursday, October 28, 2021 at 11:00 am ET to discuss the results. Participants may join the conference call via webcast or through the following dial-in numbers:Toronto and International: (416) 406-0743Toll free (Canada and the United States):  (800) 898-3989Participant passcode:   8987852#Webcast: www.alamosgold.com A playback will be available until November 28, 2021 by dialling (905) 694-9451 or (800) 408-3053 within Canada and the United States. The pass code is 5112333#. The webcast will be archived at www.alamosgold.com. About Alamos Alamos is a...

REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018. “We will greatly miss Sam and his tremendous support for Coherus. Long before joining the Coherus board, he lived a mission of providing greater access to life-changing medicines,” said Denny Lanfear, CEO of Coherus. “We were privileged to benefit from his guidance and counsel during his time on our Board, and I will forever be grateful for his service. The entire Coherus team offers our condolences to the Nussbaum family at this time.” From 2000 to 2016, Dr. Nussbaum served...

Highlights of fiscal year 2021Strengthened balance sheet with initial public offering (“IPO”) raising gross proceeds of $24.0 million Completed acquisition of Redeeem, now Troika IO, and launched new division, Troika Labs Continued focus on significant growth strategy post-COVID coupled with synergistic acquisitions Operating cost reduction to effectively manage business environment while selectively adding new strategic growth enginesSignificant highlights after the periodKey new business wins including Wilson Sporting Goods, F45 Fitness, PointsBet, Pac-12 and VSPN Accelerating expansion in fast growing gaming and Esports market Demand for client services recovering in Q1 2022 with pipeline growingNew client growth returning to pre-pandemic levels Strong net revenue recovery expected to continue in fiscal 2022 With tone of business...

MannKind Corporation facility in ConnecticutExterior of MannKind Corporation’s facility in Danbury, Conn.WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing. “We are pleased to enter into this sale-leaseback transaction and unlock value tied up in our manufacturing facility that translates directly into non-dilutive capital to support our company’s growth and development strategy,” said Michael Castagna, PharmD,...

VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. and its 100% owned subsidiary Almadex Royalties Limited, (collectively “Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce the completion of the previously announced sale of its 2% net smelter return royalty on the Elk Property to Star Royalties Ltd. (“Star Royalties”) (TSXV: STRR, OTCQX: STRFF), as further described in the Company’s press release of September 28, 2021. Almadex currently has approximately CAD$16.5 million in cash and holds approximately 2.3% of the issued and outstanding shares of Star Royalties, not including the share purchase warrants, in addition to a mineral asset portfolio consisting of numerous exploration projects and NSR royalties in Canada, the U.S., and Mexico. The Company intends...

DAYTONA BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter 2021 after the market closes on Thursday, October 28, 2021. A conference call to discuss its financial and operating results is scheduled for Friday, October 29, 2021 at 9:00 AM ET (the “Earnings Call”). Shareholders and interested parties may access the Earnings Call via teleconference or webcast:Teleconference:  USA (Toll Free) 1-844-200-6205  International 1-929-526-1599     To access the conference call, enter 094458 when prompted.     Webcast: https://www.incommglobalevents.com/registration/q4inc/8800/cto-q3-2021-earnings-call/To participate via teleconference, please dial-in approximately 10 minutes prior to the...